Literature DB >> 31405852

Isavuconazole Diffusion in Infected Human Brain.

Claire Rouzaud1, Vincent Jullien2, Anne Herbrecht3, Bruno Palmier4, Simona Lapusan5, Marjolaine Morgand1, Romain Guéry1, Amélie Dureault1, François Danion1, Stéphanie Puget6, Lauriane Goldwirt2, Fanny Lanternier1,7, Olivier Lortholary8,7.   

Abstract

We report the cases of a 39-year-old woman with chronic lymphocytic leukemia and a 21-year-old man with chronic granulomatous disease treated for cerebral aspergillosis. The patients required radical surgery for infection progression despite adequate isavuconazole plasma concentration or neurological complication. We thus decided to measure the brain isavuconazole concentration. These results suggest that the concentrations of isavuconazole obtained in the infected brain tissue clearly differ from those obtained in the normal brain tissue and the cerebrospinal fluid.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  cerebral aspergillosis; isavuconazole; pharmacokinetic; therapeutic drug monitoring

Mesh：

Substances：

Year:  2019        PMID： 31405852      PMCID： PMC6761565          DOI： 10.1128/AAC.02474-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Isavuconazole treatment of a patient with disseminated mucormycosis.

Authors:  Driele Peixoto; Lisa S Gagne; Sarah P Hammond; Erin T Gilmore; Amy C Joyce; Robert J Soiffer; Francisco M Marty
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

2.  Isavuconazole brain penetration in cerebral aspergillosis.

Authors:  F Lamoth; T Mercier; P André; J L Pagani; O Pantet; R Maduri; B Guery; L A Decosterd
Journal:  J Antimicrob Chemother       Date:  2019-06-01       Impact factor: 5.790

3.  Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Authors:  Nathan P Wiederhold; Laura Kovanda; Laura K Najvar; Rosie Bocanegra; Marcos Olivo; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples.

Authors:  Balthazar Toussaint; Fanny Lanternier; Christian Woloch; Denis Fournier; Manon Launay; Eliane Billaud; Eric Dannaoui; Olivier Lortholary; Vincent Jullien
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-01-23       Impact factor: 3.205

5.  Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.

Authors:  Dimitrios P Kontoyiannis; Dominik Selleslag; Kathleen Mullane; Oliver A Cornely; William Hope; Olivier Lortholary; Rodney Croos-Dabrera; Christopher Lademacher; Marc Engelhardt; Thomas F Patterson
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

6.  Isavuconazole for Treatment of Experimental Fungal Endophthalmitis Caused by Aspergillus fumigatus.

Authors:  John M Guest; Pawan Kumar Singh; Sanjay G Revankar; Pranatharthi H Chandrasekar; Ashok Kumar
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

7.  Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.

Authors:  Annie Lee; Brendan Prideaux; Min Hee Lee; Matthew Zimmerman; Enriko Dolgov; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

8.  Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.

Authors:  Amit Desai; Anne-Hortense Schmitt-Hoffmann; Salim Mujais; Robert Townsend
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

9.  Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.

Authors:  Anne-Hortense Schmitt-Hoffmann; Kota Kato; Robert Townsend; Michael J Potchoiba; William W Hope; David Andes; Jochen Spickermann; Marlowe J Schneidkraut
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

10.  Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.

Authors:  David R Andes; Mahmoud A Ghannoum; Pranab K Mukherjee; Laura L Kovanda; Qiaoyang Lu; Mark E Jones; Anne Santerre Henriksen; Christopher Lademacher; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191
View more
  11 in total

1.  Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?

Authors:  Matthew A Miller; Yee Ming Lee
Journal:  Curr Fungal Infect Rep       Date:  2020-01-16

2.  Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.

Authors:  Stefan Schwartz; Oliver A Cornely; Kamal Hamed; Francisco M Marty; Johan Maertens; Galia Rahav; Raoul Herbrecht; Werner J Heinz
Journal:  Med Mycol       Date:  2020-06-01       Impact factor: 4.076

3.  Isolated Cerebral Mucormycosis in Immunocompetent Adults who Inject Drugs: Case Reports and Systematic Review of the Literature.

Authors:  Eric A Meyerowitz; Sarimer Sanchez; Michael K Mansour; Virginia A Triant; Marcia B Goldberg
Journal:  Open Forum Infect Dis       Date:  2020-11-13       Impact factor: 3.835

4.  Isavuconazole Treatment of Spinal Cord Invasive Aspergillosis Guided by Cerebrospinal Fluid (1,3)-β-d-Glucan Levels in a Patient with Low Interferon-Gamma and Ulcerative Colitis.

Authors:  Siobhan O'Regan; Brendan O'Kelly; Paul Reidy; Aoibhlinn O'Toole; John Caird; Cora McNally; Samuel McConkey; Eoghan De Barra
Journal:  J Fungi (Basel)       Date:  2022-05-25

Review 5.  Isavuconazole for COVID-19-Associated Invasive Mold Infections.

Authors:  Nadir Ullah; Chiara Sepulcri; Malgorzata Mikulska
Journal:  J Fungi (Basel)       Date:  2022-06-28

6.  Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?

Authors:  Alison R Novak; Mary E Bradley; Tyree H Kiser; Scott W Mueller
Journal:  Curr Fungal Infect Rep       Date:  2020-03-26

7.  Penetration of Isavuconazole in Ascites Fluid of Critically Ill Patients.

Authors:  Tobias Lahmer; Gonzalo Batres Baires; Roland M Schmid; Johannes R Wiessner; Jörg Ulrich; Maximilian Reichert; Wolfgang Huber; Fritz Sörgel; Martina Kinzig; Sebastian Rasch; Ulrich Mayr
Journal:  J Fungi (Basel)       Date:  2021-05-11

Review 8.  Aspergillosis of central nervous system in patients with leukemia and stem cell transplantation: a systematic review of case reports.

Authors:  Aref Shariati; Mojtaba Didehdar; Shahin Rajaeih; Alireza Moradabadi; Mohammad Ghorbani; Vahid Falahati; Zahra Chegini
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-06-15       Impact factor: 3.944

9.  Successful Treatment of Cryptococcal Meningitis and Cryptococcoma with Isavuconazole in a Patient Living with HIV.

Authors:  Brendan O'Kelly; Aia Mohamed; Colm Bergin; Fiona Lyons; Thomas R Rogers; Brian O'Connell; Emma Devitt
Journal:  J Fungi (Basel)       Date:  2021-05-28

10.  Isavuconazole Therapy of Disseminated and Encephalic Saprochaete Capitata Infection in an Acute Myeloid Leukemia Patient Treated with Midostaurin.

Authors:  Salvatore Perrone; Chiara Lisi; Elettra Ortu La Barbera; Cristina Luise; Miriam Lichtner; Corrado Girmenia; Giuseppe Cimino
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-05-01       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.